timothy sykes logo
KOD Stock Explodes As Phase 3 Catalyst Frenzy Hits Thumbnail
G Google News

KOD Stock Explodes As Phase 3 Catalyst Frenzy Hits

TIM SYKES•UPDATED SEP. 28, 2026, 12:33 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Promising clinical trial progress for Kodiak Sciences Inc drives bullish sentiment as its stocks have been trading up by 171.13 percent

Key Takeaways

  • UBS reiterates a Buy on Kodiak Sciences with an $80 price target, leaning on Phase III wet AMD trials that aim to match Eylea while stretching dosing intervals.
  • Multiple KOD data catalysts cluster into year-end, with September topline, an AAO October showcase, and December readouts setting up an event-heavy trading calendar.
  • Goldman Sachs restarts coverage on Kodiak Sciences at Neutral with a $36 target, acknowledging biotech sector strength but staying cautious on stock-specific upside.
  • Pivotal Phase 3 DAYBREAK topline data for Zenkuda and KSI-501 on 2026/09/28 could redefine Kodiak Sciences’ retina pipeline and drive a violent re-rating in KOD.

Candlestick Chart

Live Update At 12:32:43 EDT: On Monday, September 28, 2026 Kodiak Sciences Inc stock [NASDAQ: KOD] is trending up by 171.13%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

KOD just showed traders what a true catalyst squeeze looks like. Shares of Kodiak Sciences exploded from a prior close around the low $30s to finish near $87.71 on 2026/09/28, a stunning multi-bagger in a single session. The daily range was wild — KOD opened near $61.71, traded as low as $60.49, and ripped to $89.69. That kind of intraday expansion tells you one thing: aggressive event-driven trading money piled in.

Zooming out, KOD had been stuck around $32–$36 for weeks. The chart shows choppy action in that tight band with no real trend. Then the run started, fueled by anticipation of Phase 3 data and bullish Street calls. On the intraday 5‑minute chart, Kodiak Sciences blasted from the $40s in premarket to the high $80s by midday, with repeated flag-and-go patterns and shallow pullbacks — textbook momentum behavior.

More Breaking News

Financially, Kodiak Sciences is still a classic clinical-stage biotech story. The latest quarter shows a net loss of about $65.6M, heavy R&D of roughly $56.1M, and operating cash outflow near $46.2M. KOD holds around $132.1M in cash, with a current ratio of 2.5, so runway is decent but not endless. For traders, that means fundamentals are binary: the DAYBREAK data will matter far more than current earnings.

Why Traders Are Watching KOD Into DAYBREAK

KOD is now a pure catalyst battleground. UBS has planted a flag with a Buy rating on Kodiak Sciences and an $80 price target, arguing that Phase III wet AMD trials for tarcocimab and KSI‑501 are likely to be non‑inferior to Eylea — the current benchmark therapy. The kicker is dosing. If KOD’s drugs can stretch treatment intervals, the commercial narrative shifts from “me‑too” to “meaningfully more convenient,” which can support premium pricing and strong adoption.

Traders love that kind of asymmetric setup. Before this latest squeeze, KOD was trading around $31. UBS framed that as a pullback and clear upside versus their $80 target. Now, with Kodiak Sciences ripping above that level, the market is front‑running the DAYBREAK topline and the rest of the news pipeline. You’ve got September data, an American Academy of Ophthalmology (AAO) presentation in October, and more readouts into December — essentially a rolling series of volatility events.

The Street isn’t one‑sided, though. Goldman Sachs restarted coverage on Kodiak Sciences at Neutral with a $36 target. They like the biotech sector overall — pointing to M&A, clinical wins, and a friendlier regulatory backdrop — but they’re not ready to chase KOD in the same way UBS is. For disciplined traders, that split is valuable. It shows there is serious debate over how much good news is already priced in.

Meanwhile, the company has circled 2026/09/28 for DAYBREAK topline Phase 3 results for Zenkuda (tarcocimab tedromer) and KSI‑501 in wet AMD. That is the event driving this move. If Kodiak Sciences delivers clean, non‑inferior data with better dosing schedules, KOD can justify a high‑beta, high‑valuation profile. If not, the air pocket below current levels is obvious on the chart.

Conclusion

For active traders, KOD is now one of the purest event-driven plays on the board. Kodiak Sciences is spending heavily — about $56.1M in quarterly research expense — and posting steep negative returns on equity and assets. None of that scares momentum traders when there is a clear binary catalyst with real commercial stakes. The market is telling you the same thing: KOD’s recent blast from the $30s to high $80s is a collective bet on DAYBREAK and the broader retina pipeline.

The key is to respect both sides of the wall of worry. UBS sees Kodiak Sciences as a high-conviction opportunity with that $80 target, anchored in expectations of non‑inferiority versus Eylea and extended dosing. Goldman Sachs is more restrained, parking its target at $36 even while acknowledging supportive sector winds. Those contrasting views define the risk/reward window.

As always, this is trading, not hope. Data will rule. When Kodiak Sciences posts its Phase 3 DAYBREAK topline on 2026/09/28, KOD is likely to gap hard in one direction. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.”. Traders in the Tim Sykes community are drilled on this mindset: “Cut losses quickly and let truly great trades work.” Apply that to KOD — size small, respect the volatility, and let the chart react to the science. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”